Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here for this GPCR stock update.

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled ...

Peer-reviewed study characterizes in vitro and ex vivo activities of novel antibody agonists generated using Abalone ...

Researchers analyzed the thermodynamics of doxepin binding to the histamine H1 receptor. The findings highlight the ...

Nxera Pharma has moved to cut performance-linked remuneration for its top executives following the release of its full-year 2025 financial results. The company said it aims to underscore disciplined ...

G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize hormones, neurotransmitters, and drugs. These receptors regulate a wide ...

G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize hormones ...

Mr. Takeo Morooka nominated for appointment as new External DirectorMs. Miwa Seki and Mr. Noriaki Nagai to retire from the Board of DirectorsTokyo, Japan and Cambridge, UK, 13 February 2026 - Nxera ...

Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an ...

Understanding the thermodynamic basis of ligand recognition by G-protein-coupled receptors (GPCRs), especially in terms of ...

The intestinal epithelium undergoes rapid renewal every 3–5 days, a process driven by intestinal stem cells (ISCs) located at the base of crypts.

New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January ...